Changes in mutational status during third-line treatment for metastatic colorectal cancer - Results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma

International Journal of Cancer

Volumn 135, Issue 9, 2014, Pages 2215-2222

  Spindler, Karen Lise Garm ^a,b   Pallisgaard, Niels ^a   Andersen, Rikke Fredslund ^a   Jakobsen, Anders ^a  

^a LILLEBAELT HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

cetuximab and irinotecan; cfDNA; KRAS; metastatic colorectal cancer; plasma

Indexed keywords

B RAF KINASE; CETUXIMAB; COMPLEMENTARY DNA; DNA; IRINOTECAN; K RAS PROTEIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; ONCOGENE K RAS; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUANTITATIVE ANALYSIS; TUMOR LOCALIZATION; TUMOR VOLUME; VERY ELDERLY;

CETUXIMAB AND IRINOTECAN; CFDNA; KRAS; METASTATIC COLORECTAL CANCER; PLASMA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROGNOSIS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84906245875     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28863     Document Type: Article

References (27)

1. Qiu LX, Mao C, Zhang J, et al. Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: a meta-analysis of 22 studies. Eur J Cancer 2010; 46: 2781-7.
2. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-34.
3. Santini D, Loupakis F, Vincenzi B, et al. High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. Oncologist 2008; 13: 1270-5.
4. Italiano A, Hostein I, Soubeyran I, et al. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications Ann Surg Oncol 2010; 17: 1429-34.
5. Baldus SE, Schaefer KL, Engers R, et al. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 2010; 16: 790-9.
6. Knijn N, Mekenkamp LJ, Klomp M, et al. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer 2011; 104: 1020-6.
7. Goranova TE, Ohue M, Shimoharu Y, et al. Dynamics of cancer cell subpopulations in primary and metastatic colorectal tumors. Clin Exp Metastasis 2011; 28: 427-35.
8. Richman SD, Chambers P, Seymour MT, et al. Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing. Anal Cell Pathol 2011; 34: 61-6.
9. Bouchahda M, Karaboué A, Saffroy R, et al. Acquired KRAS mutations during progression of colorectal cancer metastases: possible implications for therapy and prognosis. Cancer Chemother Pharmacol 2010; 66: 605-9.
10. Mancuso A, Sollami R, Recine F, et al. Patient with colorectal cancer with heterogeneous KRAS molecular status responding to cetuximab-based chemotherapy. J Clin Oncol 2010; 20:28: e756-8.
11. Diaz LA, Jr, Williams RT, Wu J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012; 486: 537-40.
12. Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012; 486: 532-6.
13. Shapiro B, Chakrabarty M, Cohn EM, et al. Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease. Cancer 1983; 51: 2116-20.
14. van der Vaart M, Pretorius PJ,. Is the role of circulating DNA as a biomarker of cancer being prematurely overrated? Clin Biochem 2010; 43: 26-36.
15. Stroun M, Lyautey J, Lederrey C, et al. Alu repeat sequences are present in increased proportions compared to a unique gene in plasma/serum DNA: evidence for a preferential release from viable cells? Ann NY Acad Sci 2001; 945: 258-64.
16. Li CN, Hsu HL, Wu TL, et al. Cell-free DNA is released from tumor cells upon cell death: a study of tissue cultures of tumor cell lines. Clin Lab Anal 2003; 17: 103-7.
17. Suzuki N, Kamataki A, Yamaki J, et al. Characterization of circulating DNA in healthy human plasma. Clin Chim Acta 2008; 387: 55-8.
18. Jung K, Fleischhacker M, Rabien A,. Cell-free DNA in the blood as a solid tumor biomarker-a critical appraisal of the literature. Clin Chim Acta 2010; 411: 1611-24.
19. Spindler KL, Pallisgaard N, Vogelius I, et al. Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. Clin Cancer Res 2012; 18: 1177-85.
20. Garm Spindler KL, Pallisgaard N, Rasmussen AA, et al. The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer. Ann Oncol 2009; 20: 879-84.
21. Fearon ER, Vogelstein B,. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-67.
22. Attolini CS, Cheng YK, Beroukhim R, et al. A mathematical framework to determine the temporal sequence of somatic genetic events in cancer. Proc Natl Acad Sci USA 2010; 107: 17604-9.
23. Linardou H, Briasoulis E, Dahabreh IJ, et al. All about KRAS for clinical oncology practice: gene profile, clinical implications and laboratory recommendations for somatic mutational testing in colorectal cancer. Cancer Treat Rev 2011; 37: 221-33.
24. Morgan SR, Whiteley J, Donald E, et al. Comparison of KRAS mutation assessment in tumor DNA and circulating free DNA in plasma and serum samples. Clin Med Insights Pathol 2012; 5: 15-22.
25. Giessen C, Laubender RP, von Weikersthal LF, et al. Early tumor shrinkage in metastatic colorectal cancer: retrospective analysis from an irinotecan-based randomized first-line trial. Cancer Sci 2013; 104: 718-24.
26. Maughan TS, Adams RA, Smith CG, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011; 377: 2103-14.
27. Tveit KM, Guren T, Glimelius B, et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol 2012; 30: 1755-62.